Fracture hospitalizations between years 2000 and 2007 in Switzerland: a trend analysis
- 355 Downloads
In Switzerland, the total number and incidence of hospitalizations for major osteoporotic fractures increased between years 2000 and 2007, while hospitalizations due to hip fracture decreased. The cost impact of shorter hospital stays was offset by the increasing cost per day of hospitalization.
The aim of the study was to establish the trends and epidemiological characteristics of hospitalizations for major osteoporotic fractures (MOF) between years 2000 and 2007 in Switzerland.
Sex- and age-specific trends in the number and crude and age-standardized incidences of hospitalized MOF (hip, clinical spine, distal radius, and proximal humerus) in women and men aged ≥45 years were analyzed, together with the number of hospital days and cost of hospitalization, based on data from the Swiss Federal Statistical Office hospital database and population statistics.
Between 2000 and 2007, the absolute number of hospitalizations for MOF increased by 15.9% in women and 20.0% in men, mainly due to an increased number of non-hip fractures (+37.7% in women and +39.7% in men). Hospitalizations for hip fractures were comparatively stable (−1.8% in women and +3.3% in men). In a rapidly aging population, in which the number of individuals aged ≥45 years grew by 11.1% (women) and 14.6% (men) over the study period, the crude and age-standardized incidences of hospitalizations decreased for hip fractures and increased for non-hip MOF, both in women and men. The length of hospital stay decreased for all MOF in women and men, the cost impact of which was offset by an increase in the daily costs of hospitalization.
Between years 2000 and 2007, hospitalizations for MOF continued to increase in Switzerland, driven by an increasing number and incidence of hospitalizations for non-hip fractures, although the incidence of hip fractures has declined.
KeywordsCost Epidemiology Fractures Hip Osteoporosis Switzerland
This work was supported by a research grant from Amgen Switzerland AG. We are grateful to Dr. Philippe Kress, Kressmed, Glattbrugg, Switzerland for his contribution to data analysis and his critical review of the manuscript. Amgen (Europe) GmbH and GlaxoSmithKline Ltd provided funds to Bioscript Stirling Ltd for editing and styling support.
Conflicts of interest
K. Lippuner has received research grants through the Osteoporosis Policlinic, University of Bern from Amgen, Novartis, Roche, Servier, and MSD. He has received speaker fees and/or was a member of a paid advisory board of Amgen, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Nycomed Roche, and Servier. A. Popp has received consulting fees from Amgen, Eli Lilly, and MSD and also Speakers bureau from Daiichi-Sankyo, and Synthes. P. Schwab, C. Senn, and R. Perrelet have nothing to declare. M. Gitlin and T. Schaufler are employees of Amgen and may own stock and/or stock options.
- 1.(1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–650Google Scholar
- 13.Maravic M, Taupin P, Landais P et al (2010) Change in hip fracture incidence over the last 6 years in France. Osteoporos Int. doi: 10.1007/s00198-010-1255-9
- 22.(2009) Swiss Federal Statistical Office. Plausibility of medical statistics: the MedPlaus 5.0 concept. Available online under ≤http://www.freudiger.com/download/mp5_konzept_D_20091029.pdf≥. Accessed Oct 2010
- 23.(2004) Swiss Federal Statistical Office. Data quality evaluation of medical statistics in 1998–2001. Available online under ≤http://www.bfs.admin.ch/bfs/portal/de/index/themen/14/22/publ.html?publicationID=1306≥. Accessed Oct 2010
- 24.Lewinnek GE, Kelsey J, White AA 3rd et al (1980) The significance and a comparative analysis of the epidemiology of hip fractures. Clin Orthop Relat Res 152:35–43Google Scholar
- 25.(2009) Swiss Federal Statistical Office. Hospital statistics between year 2000 and year 2007. Available online under http://www.bfs.admin.ch/bfs/portal/de/index/themen/14/03/01/data/01.html and http://www.bfs.admin.ch/bfs/portal/de/index/themen/14/03/01/key/01.html. Accessed 15 Feb 2010
- 27.Mathers CD, Murray CJL, Lopez AD et al (2001) World Health Organization global programme on evidence for health policy. Discussion Paper No. 38 http://www.who.int/healthinfo/paper38.pdf. Accessed 13 May 2006
- 28.Bundesamt für Statistik: Mortality and life expectancy tables. http://www.bfs.admin.ch/bfs/portal/de/index/themen/01/06/blank/key/04.html. Accessed 20 Feb 2010
- 29.Bundesamt für Statistik. Szenarien zur Bevölkerungsentwicklung der Schweiz 2005–2050. http://www.bfs.admin.ch/bfs/portal/de/index/news/publikationen.Document.83713.pdf. Accessed 14 May 2008
- 43.Looker AC, Melton LJ 3rd, Harris TB et al (2010) Prevalence and trends in low femur bone density among older US adults: NHANES 2005–2006 compared with NHANES III. J Bone Miner Res 25:64–71Google Scholar
- 47.Hulme PA, Krebs J, Ferguson SJ et al (2006) Vertebroplasty and kyphoplasty: a systematic review of 69 clinical studies. Spine (Phila Pa 1976) 31:1983–2001Google Scholar
- 48.(2004) 5-year comparison of the inpatient and outpatient costs between 1999 and 2003. Swiss Health Observatory OBSAN. http://www.obsan.admin.ch/bfs/obsan/de/index/05/01.Document.105404.pdf. Accessed 16 Jun 2010
- 50.Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645PubMedCrossRefGoogle Scholar